Chengdu Kanghong Pharmaceutical (SHE:002773) subsidiary Chengdu Kanghong Biotechnology obtained a drug registration certificate from China's National Medical Products Administration for an additional indication of its Conbercept ophthalmic injection, according to a Friday filing with the Shenzhen Stock Exchange.
The permit is for the indication of retinopathy in preterm infants. The drug is already indicated for neovascular or wet age-related macular degeneration and visual impairment caused by choroidal neovascularization, the filing said.